Cardiogenic Shock Remains Higher in Comorbid ACS, Diabetes
Patients with acute coronary syndrome and diabetes have significantly higher rates of cardiogenic shock and lower rates of revascularization.
Acute Coronary Syndrome
Evolocumab Rapidly Reduces LDL-C When Added to High-Intensity Statin in ACS
Researchers evaluated how feasible, safe, and effective evolocumab is at lowering low-density lipoprotein cholesterol when initiated in patients hospitalized with acute coronary syndrome.
Complete Revascularization Further Reduces CV Risk in STEMI
Investigators sought to determine whether PCI of nonculprit lesions further reduces risk for cardiovascular death or myocardial infarction in patients with STEMI.
Access Site Complication Rate Unchanged Despite Increase in Transradial PCI Use
Investigators examined the relationship between trends in primary and secondary vascular access sites and vascular access site complications among a cohort of patients who underwent PCI.
Adjusted Endocardial Voltage Cut-Offs Proposed for Postinfarct LV Remodeling
Investigators sought to determine novel reference cutoffs for normal unipolar voltage and bipolar voltage that would be adapted for left ventricular remodeling.
Biodegradable Polymer Sirolimus-Eluting Stents May Be Superior for STEMI
For patients with STEMI undergoing primary PCI, there were fewer target lesion failures at one year in those receiving biodegradable polymer sirolimus-eluting stents.
Anemia Associated With Higher Mortality Rates in Acute Coronary Syndrome
Investigators evaluated the relationship among baseline anemia and ischemic events, bleeding events, and mortality in patients treated primarily with P2Y12 inhibitors during percutaneous coronary intervention for acute coronary syndrome.
Alirocumab Reduces Risk for MACE in Polyvascular Disease
Further studies are needed to identify other subgroups of patients with atherosclerosis who stand to gain substantial benefit from PCSK9 inhibition.
Decreased Cardiovascular Risk Associated With Ezetimibe in Acute Coronary Syndrome
Investigators sought to identify the cardiovascular effects of adding ezetimibe to statin therapy in patients with acute coronary syndrome and dyslipidemia.
No Difference in Device End Points for Biodegradable vs Durable Everolimus Polymer Stents
Investigators evaluated the efficacy and safety of a thin-strut, biodegradable-polymer everolimus-eluting stent and a thin-strut, durable-polymer everolimus-eluting stent.
